Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Category: #health  By Pankaj Singh  Date: 2019-10-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Nature Tech Corp partners with Aldevron for gene therapy manufacturing

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and pharmaceutical firms in the field are increasingly forging collaborations and partnerships.

Aldevron, a US-based biotechnology company focused on the creation of plasmids, RNA as well as gene-editing enzymes used by pharmaceutical firms in clinical trials, reportedly announced a new licensing partnership agreement with the Nebraska-based Nature Technology Corporation (NTC).

The company announced the instant availability of antibiotic-free RNA-OUT and Nanoplasmids™ technology for utilization in gene therapy manufacturing.

Aldevron can now offer its clients the option of utilizing the plasmid technology of NTC to facilitate a more efficient system for producing viral vectors that are used in cell and gene therapy. Furthermore, gene and cell therapy firms keen to use NTC’s technology can now directly go to Aldevron for their production needs without obtaining a license from NTC first.

CEO at Aldevron, Michael Chambers stated that researchers of gene and cell therapy continue to make amazing discoveries that would improve lives for several millions of people.

Chambers further added that the company is committed to offering the best production technologies to support breakthrough treatments. The company’s partnership with NTC allows the company to offer plasmid technology that immensely improves the manufacturing procedure and decreases regulatory risk, which further results in a faster time and reduced costs to patients.

The domains of gene and cell therapy are growing with the approvals of Yescarta™ and Kymriah™ CAR-T cancer treatments and Luxturna™ to treat a rare genetic ocular disease, Leber congenital amaurosis. With around 3,000 clinical studies underway, enhancements in manufacturing are needed to provide the capacity for growth accommodation in research as well as anticipated commercial products.

The NTC technology, coupled with the unequaled throughput and scale of Aldevron, assure users will get the products they require.

CEO of NTC, Clague Hodgson stated that the company’s RNA-OUT and Nanoplasmid technology has been under development for 12 years, showcasing demonstrable advantages for the manufacturing of viral vectors.

Hodgson added that the company is thrilled to partner with Aldevron to further make this amazing technology immediately available to its customers so that they could avoid the expense and delay associated with licensing procedures, thereby removing the barriers to delivering transformative therapies to patients.

 

Source credit: https://www.globenewswire.com/news-release/2019/10/22/1932931/0/en/Aldevron-Nature-Technology-Corporation-team-up-to-offer-Nanoplasmids-for-gene-therapy-manufacturing.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Appili gets FDA approval to expand the clinical trial of favipiravir
Appili gets FDA approval to expand the clinical trial of favipiravir
By Pankaj Singh

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application ...

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
By Pankaj Singh

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The tria...

Amazon cleared by UK regulators to buy 16% stake in Deliveroo
Amazon cleared by UK regulators to buy 16% stake in Deliveroo
By Pankaj Singh

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to ...